|
| Press Releases |
|
 |
|
| Friday, October 30, 2020 |
|
|
Avance Clinical Wins MasterControl 2020 Innovation Excellence Award |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Biotechs get scalable early to late phase clinical offering from Avance Clinical and Cromos Pharma - announced at Bio-Europe 2020 |
| Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in Australia and Central/Eastern Europe, respectively, are successfully collaborating on a scalable clinical solution for biotechs. more info >> |
|
| Tuesday, September 22, 2020 |
|
|
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America |
| The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions more info >> |
|
| Friday, September 4, 2020 |
|
|
Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study, Atossa's Second COVID-19 Therapeutic Development Program |
| The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical has been contracted to conduct a clinical study of Atossa Therapeutics' proprietary drug candidate AT-301, to be administered by nasal spray. Avance has successfully completed multiple clinical studies of Atossa's proprietary Endoxifen. more info >> |
|
| Thursday, July 9, 2020 |
|
|
Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award |
| The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. more info >> |
|
| Tuesday, June 9, 2020 |
|
|
TrialTrove Data Shows Australia is Open for Business says Avance Clinical at BIO Digital 2020 |
| The leading Australian CRO for biotechs, Avance Clinical announced at BIO Digital today that Australia currently has 2,413 trials planned or ongoing. more info >> |
|
| Thursday, April 9, 2020 |
|
|
Australian CRO Avance Clinical Designated an Essential Service as Strong Demand from Sponsors Continues Amid COVID-19 Crisis |
| Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. more info >> |
|
| Thursday, April 2, 2020 |
|
|
Avance Clinical on Top Reasons APAC Biotech Clients Choose Australia for Clinical Trials |
| Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. more info >> |
|
| Friday, March 20, 2020 |
|
|
Australian CRO, Avance Clinical is Uniquely Positioned for COVID-19 Vaccines and Therapies Clinical Trials |
| Australian CRO Avance Clinical said today that Australia's fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
|
|
|
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
|
|
|
Blockpass and RWA Inc. Partner to Effect Verifiable Trust in Real World Asset & DePIN Tokenization 
Oct 17, 2025 17:00 HKT/SGT
|
|
|
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
|
|
|
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
|
|
|
Canada Backs Advanced Tokenization and Distributed Federated Learning Research with Over $3 Million in Funding
Oct 16, 2025 22:45 HKT/SGT
|
|
|
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
|
|
|
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
|
|
|
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
|
|
|
Kincora Appoints Kerry Stevenson and Michelle Borromeo to the Advisory Board
Oct 16, 2025 20:09 HKT/SGT
|
|
|
45th Electronics Fair and electronicAsia attract some 60,000 buyers
Oct 16, 2025 19:06 HKT/SGT
|
|
|
Radisson Expands Ongoing Step-Out Drill Program at O'Brien to 140,000 Metres
Oct 16, 2025 18:39 HKT/SGT
|
|
|
How DPC Dash-Domino's Pizza China Is Capturing China's Pizza Market
Oct 16, 2025 14:30 HKT/SGT
|
|
|
SERES Passes HKEX Listing Hearing - First 'A+H' Dual-Listed Premium NEV Maker Poised for Hong Kong Debut
Oct 16, 2025 14:28 HKT/SGT
|
|
|
Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models
Oct 16, 2025 13:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
